ArticlePeerJ2025
Analysis of novel therapeutic targets and construction of a prognostic model for hepatocellular carcinoma.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cuproptosis: potential new direction in liver-related diseases research and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Multi-omics analysis of BTF3L4 as a prognostic and immune biomarker in hepatocellular carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of patients with hepatocellular carcinoma (HCC) remains suboptimal due to limited biomarkers. Although ferroptosis and cuproptosis have emerged as promising therapeutic targets, their prognostic significance in HCC remains unclear. Methods: This study analyzed the expression of ferroptosis- and cuproptosis-related genes associated with survival in HCC, utilizing datasets from The Cancer Genome Atlas and the Gene Expression Omnibus. The impact of clinical factors on patient prognosis was also analyzed. The key findings were validated using the Human Protein Atlas database, quantitative real-time PCR, and Western blot (WB) analyses. Results: Prognostic modeling identified six ferroptosis-related genes (SLC1A5, SLC7A11, CBS, GABARAPL1, FLT3, and MT3) and three cuproptosis-related genes (ADM, CDKN2A, and GLS) significantly associated with HCC prognosis. A robust risk assessment model was developed with strong predictive power. The inflammatory cell apoptotic process is an immune-related pathway that is commonly enriched by ferroptosis and cuproptosis genes. Immune cell profiling using CIBERSORT revealed significant differences in macrophages, naive B cells, mast cells, monocytes, memory CD4+ T cells, and CD8+ T cells. Conclusions: This study, for the first time, integrated multi-omics data and experimental verification to establish a prognostic model of HCC based on the ferroptosis gene. It can be used to dynamically monitor HCC using blood tests and provide a new target for personalized immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.